Nutriband Inc. (NTRB) Research

Nutriband Inc. specializes in developing a diverse range of pharmaceutical products delivered via transdermal patches. The company's most advanced program centers on AVERSA fentanyl, an innovative fentanyl transdermal system engineered to prevent abuse. This extended-release patch provides healthcare professionals and patients with a continuous opioid therapy solution for the ongoing management of chronic pain. Its development pipeline also includes other treatments, such as AVERSA buprenorphine and AVERSA methylphenidate. Additionally, Nutriband is working on exenatide for individuals with type 2 diabetes and follicle stimulating hormone as a treatment for infertility. The company also holds a licensing agreement with Rambam Med-Tech Ltd. to further the development of RAMBAM Closed System Transfer Devices. Nutriband Inc. was founded in 2016 and its main offices are located in Orlando, Florida.

Market snapshot

Symbol
NTRB
Price
$2.90
Day change
-5.23%
Market cap
$35.3M
P/E ratio
-4.36x
52-week range
2.9-11.678
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 3 months

Peer companies

  • Adicet Bio, Inc. (ACET)
  • Acrivon Therapeutics, Inc. Common Stock (ACRV)
  • Adagene Inc. (ADAG)
  • CervoMed Inc. (CRVO)
  • Fortress Biotech, Inc. (FBIO)
  • Gain Therapeutics, Inc. (GANX)
  • Lite Strategy, Inc. (LITS)
  • Relmada Therapeutics, Inc. (RLMD)

Recent insider activity

  • Sheridan Gareth — trade (0 shares) on 2025-01-31
  • Sheridan Gareth — A-Award (29333 shares) on 2025-01-29
  • Sheridan Gareth — A-Award (97500 shares) on 2024-03-20
  • Goodman Gerald — A-Award (17667 shares) on 2025-01-23
  • Goodman Gerald — A-Award (75000 shares) on 2024-03-19

Open Nutriband Inc. (NTRB) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.